Madrigal Pharmaceuticals
MDGL
91 hedge funds and large institutions have $143M invested in Madrigal Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 22 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
77% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 22
8% more funds holding
Funds holding: 84 → 91 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $146M → $143M (-$3.51M)
47% less call options, than puts
Call options by funds: $373K | Put options by funds: $698K
Top Buyers
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$16.8M |
| 2 |
AC
Armistice Capital
New York
|
+$7.94M |
| 3 |
JG
Jefferies Group
New York
|
+$7.94M |
| 4 |
Jennison Associates
New York
|
+$7.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.74M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$1.07M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.06M |
| 3 |
Millennium Management
New York
|
-$933K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$612K |
| 5 |
D.E. Shaw & Co
New York
|
-$410K |
MDGL Hedge Fund Activity: Q1 2015 in Review
91 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2015, worth a combined $143M — down 2.4% from $146M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MDGL positions and 8 closed out — a net gain of 7 holders — while 39 added to existing stakes and 22 trimmed.
The largest buyer was Caxton Corporation, adding an estimated $16.8M. The largest seller was Morgan Stanley, cutting an estimated $1.07M.
- 91 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2015, up from 84 in Q4 2014.
- Funds reported $143M of Madrigal Pharmaceuticals stock for Q1 2015, down 2.4% quarter-over-quarter.
- 15 funds opened new Madrigal Pharmaceuticals positions in Q1 2015 and 8 closed out, a net change of +7 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2015 was Caxton Corporation, an estimated $16.8M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2015 was Morgan Stanley, an estimated $1.07M sold.
Based on aggregated 13F filings for Q1 2015.